## 3 Results  
A total of 102 patients (62 males and 40 females) were included in the study. Clinical hematological characteristics and demographic data are summarized in Table 1.  
Following HSCT, 20 patients (19.6%) developed acute GVHD, and 35 patients (34.3%) developed chronic GVHD. Forty-three patients (42.1%) developed oGVHD; the median time from HSCT to the onset of oGVHD was 332 days. Data were retrieved on a mean time of 151 \(\pm\) 43 days post operatively. Ocular parameters were compared between No oGVHD and oGVHD and summarized in Table 2, but no statistically significant difference was found between groups. \begin{table}
\begin{tabular}{c c c} \hline \hline
**Demographic Data** & **Patient Number** & **\% vs. Total** \\ \hline Females & 40 & 39.2 \\ Males & 62 & 60.8 \\ Age (yrs.) all & 47.5 (18–65) [44, 6–50.3] & \\ Females & 49.0(21–61) [45, 46–53] & \\ Males & 47 (18–65) [41–50] & \\ \hline \multicolumn{3}{c}{**Haematological History**} \\ \hline \multirow{3}{*}{SCMs} & _Disorders_ & \\  & ALL & 26 & 25.4 \\  & AML & 30 & 29.4 \\  & MDS & 10 & 9.8 \\  & CML & 6 & 5.8 \\  & HL & 10 & 9.8 \\  & NHL & 12 & 11.7 \\  & MM & 6 & 5.8 \\  & CLL & 2 & 1.9 \\ \hline \multicolumn{3}{c}{**Time from diagnosis to HSCT (days)**} & 265 (123–2432) [183–421] & \\ \hline \multicolumn{3}{c}{**Previous chemotherapy**} \\ \hline \(\leq\)3 cycles & 62 & 60.7 \\ \(>\)3 cycles & 40 & 39.3 \\ \hline \multicolumn{3}{c}{**HSCT Parameter**} \\ \hline \multicolumn{3}{c}{**Donor characteristics**} \\ \hline Age (yrs) & 29 (0–56) [27–33] & \\ MUD & 80 & 78.4 \\ MRD & 22 & 21.6 \\ HLA mismatch & 58 & 56.8 \\ Sex mismatch & 45 & 41.1 \\ \hline \multicolumn{3}{c}{**Conditioning regimen**} \\ \hline Reduced & 24 & 23.5 \\ Mieolablative & 78 & 76.6 \\ \hline \multicolumn{3}{c}{**Stem Cell source**} \\ \hline Bone marrow & 28 & 27.4 \\ Peripheral Blood & 68 & 66.6 \\ Cord Blood & 6 & 5.8 \\ \hline \hline \end{tabular}  
ALL = acute lymphoblastic leukemia, AML = acute myeloid leukemia, HL = Hodgkin lymphoma, CML = chronic, myeloid leukemia, NHL = non-Hodgkin lymphoma, MM = multiple myeloma, MDS = myelodysplastic syndrome, CLL = chronic lymphocytic leukemia. MUD = matched unrelated donors; MRD = matched related donors; LPDs = chronic lymphoproliferative disorders; SCMs = stem cell malignancies.  
\end{table} 
Table 1: Clinical and demographic data in subjects included in the study. Data are expressed as median (min-max values) (95% CI). Data from tear analysis performed pre-HSCT and post-HSCT are summarized in Table 3. TP, LACTO, LYS-C, and ZAG-2 levels significantly decreased post-HSCT as compared to pre-HSCT levels (\(p<0.0001\)). TRANSFF post-HSCT levels significantly increased (\(p<0.0001\)). ALB and LIPOC-1 levels did not exhibit statistically significant pre-post-HSCT changes. The comparison of levels in tear proteins before and after HSCT between patients developing or not oGVHD is summarized in Table 4. TP, LACTO, LYS-C, TRANSFF, and ZAG-2, but not ALB and LIPOC-1, levels showed statistically significant differences in both groups. The intra-subject individual pre-post difference (\(\Delta\) pre-post) was calculated, and compared by stratifying patients into groups, developing or not oGVHD. \(\Delta\) pre-post-ALB, LIPOC-1, and LYS-C were not found significantly different in the two groups (\(p=0.8\), \(0.9\), \(0.8\), respectively). Figure 1 summarizes the results from \(\Delta\) pre-post TP, LACTO, TRANSFF, and ZAG-2, that were found statistically significantly higher in the group developing as compared to the group not developing oGVHD.